20 filings
8-K
VTGN
VistaGen Therapeutics Inc
27 Dec 19
Regulation FD Disclosure
4:05pm
8-K
VTGN
VistaGen Therapeutics Inc
12 Dec 19
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
5:14pm
8-K
VTGN
VistaGen Therapeutics Inc
14 Nov 19
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
7:46am
8-K
VTGN
VistaGen Therapeutics Inc
8 Nov 19
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
12:00am
8-K
VTGN
VistaGen Therapeutics Inc
30 Oct 19
Other Events
12:00am
8-K
o1shsc3rj26w v1if
9 Oct 19
Regulation FD Disclosure
12:00am
8-K
9py fmr725p
25 Sep 19
Other Events
4:03pm
8-K
lguky3n9fs5bc s8a
6 Sep 19
Amendments to Articles of Incorporation or Bylaws
4:55pm
8-K
9ot8nfp
23 Aug 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:37pm
8-K
g3i4b5jfa75iid4zceqj
16 Aug 19
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
12:00am
8-K
jqthoxbiqxg vkt
23 Jul 19
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
4:31pm
8-K
1q0nai2
21 Jun 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
pcc7ucdkqp4 q5
2 May 19
Regulation FD Disclosure
5:22pm
8-K
ar54drz8
4 Apr 19
Other Events
4:10pm
8-K
67wwn51dctiq
14 Mar 19
Regulation FD Disclosure
4:50pm
8-K
424cy
4 Mar 19
Entry into a Material Definitive Agreement
4:15pm
8-K
phlxy dpt39s2h1t0
19 Feb 19
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
4:18pm
8-K
wx3op0yh
1 Feb 19
AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
12:00am
8-K
y9ytfdgkbju
15 Jan 19
VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
4:16pm
8-K
kzriua3m 99xxzz1p0y
11 Jan 19
Regulation FD Disclosure
5:30pm
- Prev
- 1
- Next